Appili Therapeutics' Grant - III Round

Appili Therapeutics raised a round of funding on April 11, 2017. Investors include National Research Council Canada.

Appili is dedicated to identifying, acquiring and advancing therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a tast…

Articles about Appili Therapeutics' Grant - III Round: